Wave reported dose-dependent, single-dose reductions in circulating Activin E at day 29 in its INLIGHT obesity study: 85% at 400 mg, 75% at 240 mg, and 56% at 75 mg (all p<0.0001). The lowest dose showed durability through six months, supporting once- or twice-yearly dosing. WVE-007 was generally well tolerated to date, and an independent monitoring committee cleared dose expansion of 600 mg and escalation beyond. The company’s core update centers on target engagement for WVE-007, a GalNAc-siRNA designed to silence INHBE, with the aim of reducing visceral fat while preserving muscle. INLIGHT is a randomized, placebo-controlled, single-dose escalation study (3:1 active: placebo) with readouts staged through mid-2026. Wave plans to begin sharing body weight and composition data in 4Q25 from the expanded 240 mg cohort and 75 mg cohort, with six-month outcomes from 240 mg in 1Q26 and from 400 mg in 2Q26. Beyond obesity, Wave advanced its RNA editing portfolio: WVE-006 for alpha-1 antitrypsin deficiency has reached protein restoration levels associated with reduced organ risk and is dosing at 600 mg in Cohort 3, with multidose data expected in 2026; WVE-008 was named the clinical candidate for PNPLA3-I148M liver disease with a 2026 CTA planned. The company also highlighted preclinical data for a single oligonucleotide capable of editing one target and silencing another. Strategically, Wave is positioning WVE-007 as an infrequent dosing option that could slot alongside GLP-1s or serve as a maintenance tool to mitigate weight regain. The differentiation thesis hinges on hepatic delivery to shift adipose biology and maintain lean mass, operational simplicity relative to chronic injectables, and compatibility with combination regimens. The tension is clear: robust target engagement is a necessary but incomplete surrogate for clinical value in obesity. The mechanism needs to convert to meaningful, durable fat loss, with favorable lean mass and cardiometabolic signals, to stand out in a market where GLP-1/GIP combinations are setting a high efficacy bar and sponsors are moving rapidly into maintenance and combo strategies. For sites, the operational footprint may be lighter on visit frequency but heavier on measurements: Activin E assays, liver function monitoring, and body composition assessments (DXA or MRI) will be critical, potentially straining imaging capacity and adding central lab dependencies. Add-on designs to GLP-1s will introduce protocol complexity around background therapy stability and potential washouts. CROs will be managing DMC-driven escalations, long follow-up windows, and imaging standardization across geographies. Regulators will focus on translation from biochemical suppression to clinical endpoints, with scrutiny on lean mass preservation and metabolic risk markers; any future maintenance positioning will also invite payer attention to adherence, retreatment intervals, and total cost of care. What matters next is the linkage between Activin E suppression and absolute percent weight and fat loss, along with lean mass trajectories relative to GLP-1 comparators. Dose selection for Phase 2 will need to balance depth and duration of effect against hepatic safety and retreatment feasibility. If Wave can deliver clinically meaningful body composition outcomes with semiannual dosing, it will have a credible case for combination use and maintenance. Parallel progress on WVE-006 and the PNPLA3 program could further de-risk the platform’s editing and extrahepatic ambitions. Watch for body composition data in 4Q25–2Q26, clarity on add-on study designs to GLP-1s, and signals that manufacturing and CMC are scaling to support large, chronic populations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
